ISPOR 21ST ANNUAL INTERNATIONAL MEETING WORKSHOP EXPLORES HOW TO MAKE PATIENTS AS PARTNERS IN RESEARCH A REALITY

Published May 24, 2016
Washington, DC—May 24, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting Workshop 13—Patients as Partners in Research—Making It a Reality—was held this afternoon in Washington, DC, USA. The Workshop discussion leaders included:
  • Rachel Harrington, PhD, Senior Research Alliances Manager, Health Economics and Clinical Outcomes Research, Astellas Medical Affairs Americas, Northbrook, IL, USA
  • Alfonso Aguarón, Project Manager, Myeloma Patients Europe, Madrid, Spain
  • Robert N. McBurney, PhD, Chief Executive Officer, Accelerated Cure Project for Multiple Sclerosis, Waltham, MA, USA
  • Holly Peay, PhD, MS, CGC, Principal Investigator, DuchenneConnect Network, Parent Project Muscular Dystrophy, and Research Scientist, RTI International, Research Triangle Park, NC, USA
Including the perspective of patients and their representatives in all stages of the research and decision making process has become increasingly important. This type of patient engagement has been cited by researchers, government agencies, and patient advocates as an essential step to improve health care delivery and outcomes. The discussion leaders provided an overview of the key components that are essential for patient engagement and collaboration in clinical research studies and in health care decision making. Engagement components range from low-level interaction through consultation to higher level collaboration through partnership and shared leadership. Presentations and slide decks from the ISPOR 21st Annual International meeting can be found here. Interested parties can follow news and developments from the meeting on social media using the hashtag #ISPORDC. ###

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Europe 2025 Plenaries and Speakers Announced

Oct 13, 2025

ISPOR announced details for its ISPOR Europe 2025. The conference is the leading global conference in Europe for health economics and outcomes research (HEOR) and is scheduled for 9-12 November in Glasglow, Scotland, UK with the theme, “Powering Value and Access Through Patient-Centered Collaboration.”
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×